Your browser version is outdated. We recommend that you update your browser to the latest version.


Our technology is based on administration of liposomes loaded with immune modulating compounds targeted to circulating monocytes in the blood after IV treatment. The liposomes are recognized specifically by monocytes within minutes after administration and subsequently phagocytosed. The liposomes are processed to endosomes where Toll Like Receptors (TLRs) 3, 7, 8 and 9 are expressed. TLRs in the endosomes recognize under normal conditions intracellular pathogens like bacteria and virus, and are essential for the immune system to fight the infection.

Our liposomes are able to deliver TLR-agonists to these receptors inside the monocytes, with subsequent activation and migration of the monocytes into tumor tissue and lymph nodes, where they phagocytose tumor cells, produce anti-cancer cytokines and activate T-cells and NK cells to fight the tumors.




Key benefits of the MonTa Biosciences' technology are:

  • Compared to systemic administration of currently used IL-2 and IFNa-treatment, which results in high systemic and low local cytokine levels with severe toxicity, our technology provides low systemic but high local anti-tumor cytokine production with reduced oxicity.
  • Proven anti-metastatic activity in experimental cancer models.
  • Monocytes are activated to secrete the anti-tumor cytokine IL-12, which is essential to activate cytotoxic T-cells to fight the tumor cells.
  • One of the first technologies to allow systemic delivery of TLR3, TLR7, TLR8 and TLR9-agonists with reduced toxicity
  • Promising technology to complement existing therapies like radiation, chemotherapy, therapeutic antibodies, biologics, kinase inhibitors and surgery.